I. Blasutig

Oncology · 2016

A researcher in the Science corpus: 1 paper; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom I. Blasutig trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Padmanee Sharma

Papers from I. Blasutig's perspective

Ordered by how strongly the researchers I. Blasutig trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  3. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
  4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
  5. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
  6. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (Journal of Experimental Medicine)
  7. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (Nature Reviews. Cancer)
  8. Hepatotoxicity with combination of vemurafenib and ipilimumab. (New England Journal of Medicine)
  9. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (Science)
  10. Hallmarks of cancer: the next generation. (Cell)

Their papers